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Abstract
Background: The receptor for advanced glycation end-products (RAGE) has been suggested to modulate lung injury in
models of acute pulmonary inflammation. To study this further, model systems utilizing wild type and RAGE knockout (KO)
mice were used to determine the role of RAGE signaling in lipopolysaccharide (LPS) and E. coli induced acute pulmonary
inflammation. The effect of intraperitoneal (i.p.) and intratracheal (i.t.) administration of mouse soluble RAGE on E. coli injury
was also investigated.
Methodology/Principal Findings: C57BL/6 wild type and RAGE KO mice received an i.t. instillation of LPS, E. coli, or vehicle
control. Some groups also received i.p. or i.t. administration of mouse soluble RAGE. After 24 hours, the role of RAGE
expression on inflammation was assessed by comparing responses in wild type and RAGE KO. RAGE protein levels
decreased in wild type lung homogenates after treatment with either LPS or bacteria. In addition, soluble RAGE and HMGB1
increased in the BALF after E. coli instillation. RAGE KO mice challenged with LPS had the same degree of inflammation as
wild type mice. However, when challenged with E. coli, RAGE KO mice had significantly less inflammation when compared
to wild type mice. Most cytokine levels were lower in the BALF of RAGE KO mice compared to wild type mice after E. coli
injury, while only monocyte chemotactic protein-1, MCP-1, was lower after LPS challenge. Neither i.p. nor i.t. administration
of mouse soluble RAGE attenuated the severity of E. coli injury in wild type mice.
Conclusions/Significance: Lack of RAGE in the lung does not protect against LPS induced acute pulmonary inflammation,
but attenuates injury following live E. coli challenge. These findings suggest that RAGE mediates responses to E. coli-
associated pathogen-associated molecular pattern molecules other than LPS or other bacterial specific signaling responses.
Soluble RAGE treatment had no effect on inflammation.
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Introduction
Acute lung injury and acute respiratory distress syndrome
(ARDS) are caused by various factors such as aspiration,
hyperoxia, bacterial pneumonia, and sepsis. Damage to the
alveolar epithelium leads to an inflammatory response mediated
by release of inflammatory cytokines from activated macrophages.
The inflammatory cytokines recruit inflammatory cells from the
blood and increase the permeability of the alveolar-capillary
membrane. As a result, proteinaceous fluid accumulates in the
lung, leading to decreased pulmonary function [1].
The receptor for advanced glycation end-products (RAGE) was
originally purified from bovine lung and was shown to have
affinity towards advanced glycation end-products [2]. RAGE
expression has since been found to be very high in the normal lung
compared to low or no expression in other tissues. Furthermore, in
contrast to most organs where RAGE expression increases with
disease [3,4]; RAGE levels decrease significantly in the injured
lung [5–8]. RAGE is primarily expressed on epithelial type I cells
[9,10] and has in recent years been implicated in various forms of
fibrosis and diabetic vascular disease [5,7,8,11–13] and more
recently in acute lung injury and sepsis [14–17].
A recent study found that i.p. administration of soluble RAGE
attenuated LPS-induced acute lung injury in mice [16]. In
addition, soluble RAGE has been shown to accumulate in the
BALF and sera of patients with acute lung injury and is thought to
be a marker of alveolar type I cell injury [18–21]. However, the
effect of these injuries on overall pulmonary RAGE expression has
not been determined. As RAGE ligands are not specific for
RAGE, the finding that soluble RAGE protected against
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LPS-induced lung injury may be due to blocking membrane
RAGE signaling or by preventing RAGE ligands from binding
other receptors. In fact, the inflammatory response against LPS is
mediated by recognition of the LPS molecule by TLR4 primarily
on macrophages. Binding of LPS to TLR4 leads to an up
regulation of pro-inflammatory cytokines [22]. One of these
cytokines, high mobility group box 1 (HMGB1), is a damage-
associated molecular pattern molecule (DAMP) that binds to and
activates TLR2- and -4 [23,24], but is also a ligand for RAGE
[2,25]. Activation of RAGE leads to activation of nuclear factor
kappa B (NF-kB), which in turn leads to a further increase in
transcription of pro-inflammatory cytokines [26,27] and a positive
feedback loop that results in sustained inflammation.
In the current study, both a LPS and a bacterial (E. coli)
pneumonia model were used to study the role of RAGE in acute
pulmonary inflammation. LPS is a pyrogenic molecule present in
the cell wall of Gram-negative bacteria such as E. coli and belongs
to the group of pathogen-associated molecular patterns, which
signals danger via receptors such as the Toll-like receptors (TLRs)
and other pattern recognition receptors [28]. In addition,
administration of purified mouse soluble RAGE to wild type mice
challenged with E. coli was performed to determine if this could
offer any therapeutic effect and to also distinguish between the
effects of membrane and soluble RAGE.
Materials and Methods
Ethics Statement
All animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee at the University of
Pittsburgh. Animals were given free access to food and water and
were cared for according to guidelines set by the American
Association for Laboratory Animal Care.
Animal experiments
The constitutive global RAGE KO strain was generated on a
C57BL/6 background [29]. C57BL/6 wild type mice were
purchased from Taconic (Germantown, NY). Only male mice
were used in the experiments.
LPS serotype 055:B5 (Sigma-Aldrich, St. Louis, MO) was
diluted in PBS. Mice received i.t. instillations of 75 mg LPS in a
total volume of 75 mL. For E. coli (ATCC, Manassas, VA,#25922)
challenge, mice received i.t. instillation of 16106 CFU’s in 50 mL
of PBS. For i.p. treatment with mouse soluble RAGE mice
received 100 mg right before E. coli instillation, control mice in the
same experiment all received an equal volume of PBS i.p. The
choice of a single soluble RAGE injection was based on prior
studies showing that i.v. administered recombinant rat soluble
RAGE has a half-life of 26 hours in rats [30]. In addition, this dose
of soluble RAGE was previously shown to be effective in LPS
induced lung injury [16]. Mice receiving both E. coli and soluble
RAGE i.t. were given 50 mg of soluble RAGE and 16106 CFU’s
in 50 mL of PBS.
Mouse soluble RAGE was purified and endotoxin removed as
previously described [31]. Biological activity of the purified soluble
RAGE was confirmed by showing concentration dependent
binding to HMGB1 (A RAGE ligand; Sigma-Aldrich) in an
ELISA like setup as previously described [10,32] (not illustrated).
Protein in PBS and PBS used for i.p. and i.t. injections/instillations
had endotoxin levels below an administration of 5 EU/kg mouse.
Endotoxin levels were determined using the limulus amebocyte
lysate single test vial assay (Associates of Cape Cod, East
Falmouth, MA).
Inflammatory cells
Mice were sacrificed by an overdose of pentobarbital sodium
(Ovation Pharmaceuticals Inc., Deerfield, IL) and the lungs were
lavaged with a single instillation of 800 mL normal saline.
Recovery of BALF was consistently above 75%. BALF cells were
counted using a Z1 Coulter Particle Counter (Beckman Coulter
Inc., Fullerton, CA) and 30,000 cells were transferred to glass
slides using a Shandon Cytospin 4 (Thermo Electron Corporation,
Pittsburgh, PA) at 750 rpm for 5 min. After 2 days of drying, cells
were stained using the Diff-Quick stain (Dade Behring Inc.,
Newark, DE), and cell differentials were determined by counting
200 cells.
Protein concentration in BALF
Protein concentration in undiluted BALF was measured in
triplicate by a standard endpoint measurement at 495 nm using
Bradford reagent with a bovine serum albumin standard curve
(Thermo Scientific, Rockford, IL).
Cytokine profile of BALF
IL-1b, IL-6, IL-12(p70), KC, MCP-1, MIP-1a, and TNF-a
concentrations were measured in BALF samples using an 8 plex
Procarta Cytokine Assay Kit – Mouse (Affymetrix, Fremont, CA).
The assay was performed in duplicate on 50 mL of BALF using a
mouse bodily fluid diluent (Affymetrix) according to manufactures
instructions and read on a LuminexTM 100 IS apparatus
(MiraiBio, Austin, TX). Some control samples had levels below
the limit of detection, labeled ND. For these samples the limit of
detection for the individual cytokines was used for the statistical
analysis. This was done under the assumption that if a statistical
significant difference could be measured using the limit of
detection, then the actual value would only strengthen the
statistics. BALFs from both strains treated with vehicle control,
LPS, and E. coli were assayed (6 groups).
Mouse Lung Slices
Mice were sacrificed by i.p. injection with sodium pentobarbital
(35 mg/kg). Lungs were perfused through the heart with cold PBS
and removed using aseptic techniques and placed into PBS
solution on ice. A McIlwain tissue chopper (Mickle Laboratory
Engineering Co. Ltd., United Kingdom) was used to cut the lungs
transversely. The slice thickness was chosen to be 0.7 mm which
was predicted by Warburg equation: C1 =C0-A/D*d2/8, where
C1 is the pO2 in the deepest layer of the slice; C0 is the pO2 at the
surface of the slice; A is oxygen uptake of the slice in mL/min/mL
of tissue; D – diffusion coefficient in mL of oxygen/cm2/min; d –
slice thickness in cm [33,34]. After being cut the slices were placed
into a 10 mm dish filled with PBS and washed with agitation. Six
pieces were placed into each well of a 6-well tissue culture plate.
Slices were maintained in RPMI-1640/HAM’S- F12 medium
(Lonza Group Ltd., Switzerland) (1:1) supplemented with 10%
FBS and 1% penicillin-streptomycin. Culture medium containing
500 ng LPS (Serotype 055:B5, Sigma-Aldrich, St. Louis, MO)
were applied 1 hour after seeding. After 24 hours the slices were
harvested in TRI-Reagent, total RNA was extracted as directed by
the manufacturer (Molecular Research Center, Cincinnati, OH)
and used for Luminex RNA assay for 5 known inflammatory
cytokines (IL-1a, IL-6, IL-1b, TNF-a and MCP-1). All experi-
ments were performed in triplicate.
Histology
Lungs used for histology were inflation fixed with 800 mL of
10% neutral buffered formalin for 8 min and then paraffin
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embedded. This was done by placing a lavage needle in a small
incision in the exposed trachea. A suture was used to tie around
the needle and trachea in order to make a tight seal. After the
8 minutes the lung was removed and placed in neutral buffered
formalin for a minimum of 6 hours, followed by 95% ethanol until
paraffin embedding. Five mm sections were H&E stained and the
sections were evaluated by light microscopy.
Myeloperoxidase assay
Lungs were perfused through the right ventricle of the heart
with 10 mL of saline to get rid of blood neutrophils, excised, flash
frozen in liquid nitrogen and stored at 280uC until use. Lungs
were homogenized in 3 mL of homogenizing buffer (50 mM
potassium phosphate/10 mM N-ethylmaleimide, pH 6.0). Follow-
ing centrifugation at 12,0006 g for 30 min at 4uC, the pellet was
washed twice in 1 mL of homogenizing buffer. The pellet was then
resuspended in 1 mL of HTAB buffer (50 mM potassium
phosphate/0.5% hexadecyltrimethylammonium bromide,
pH 6.0) by sonication. After 3 freeze thaw cycles using liquid
nitrogen and a 56uC water bath, the samples were incubated at
56uC for 2 hours. After centrifugation at 12,0006 g for 10 min,
10 mL of each sample was mixed with 890 mL of assay buffer
(50 mM potassium phosphate/0.167 mg/mL o-dianisidine dihy-
drochloride/0.0005% H2O2/0.01% HTAB, pH 6.0) and the
absorbance at 460 nm was measured on a Beckman Coulter
Spectrometer (Beckman Coulter Inc., Somerset, NJ) every 5 sec.
for 2 min. using a kinetic protocol. The myeloperoxidase activity
was determined from the slope of the curve and reported as dA/
min per lung.
Lung homogenization
Whole frozen lungs were homogenized into 3 mL of cytoplas-
mic buffer (10 mM HEPES/10 mM KCl/2 mM MgCl2/0.1 mM
EDTA/1 mM DTT/1 mM PMSF/10 mM E64/pH 7.8) and
incubated on ice for 15 min followed by centrifugation at
12,0006 g for 5 min at 4uC. The supernatant was centrifuged
again as described above; the supernatant was kept as the soluble/
cytoplasmic fraction. The cell pellet from the first centrifugation
was washed in 2 mL wash buffer (10 mM HEPES/10 mM KCl/
150 mM NaCl/0.1 mM EDTA/1 mM DTT/1 mM PMSF/
10 mM E64/pH 7.8) by vortexing and centrifuged as above. The
resulting cell pellet was resuspended in 500 mL membrane buffer
(Wash buffer with 1% NP-40) vortexed and rotated end-over-end
for 30 min at 4uC. After centrifugation as above the supernatant
was kept as the membrane fraction. Protein concentration was
measured at a 1:20 dilution as for BALF described above.
Western blotting
SDS-PAGE was performed with 5–15% gradient gels using the
glycine/2-amino-2-methyl-1,3-propanediol/HCl system as previ-
ously described [35]. Proteins were transferred onto a PVDF
membrane (Millipore, Billerica, MA) and the membrane was
blocked in 5% milk in PBS-T. The membrane was incubated with
a 1:5,000 dilution of primary antibody against RAGE generated in
rabbit as previously described [5], a 1:2,000 dilution of rabbit-anti
HMGB1 (Abcam, Cambridge, MA) or a 1:5,000 dilution of
mouse-anti b-actin (Sigma-Aldrich). After washing, the membrane
was incubated with a 1:5,000 dilution of a HRP-conjugated
donkey-anti-rabbit antibody (GE Healthcare, Buckinghamshire,
UK) or a 1:10,000 dilution of a HRP-conjugated goat-anti-mouse
antibody (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA). The membrane was developed using the enhanced
chemiluminescent plus reagent (GE Healthcare) for BALF blots or
the SuperSignal West Pico Chemiluminescent Substrate (Thermo-
Fisher) for lung homogenates and visualized on a KODAK
GelLogic 2200 Imaging system (Carestream Health, Rochester,
NY). Loading control on lung homogenate blots was performed by
stripping the membrane for 1 hr (25 mM Glycine, 1% SDS, pH 2)
and reprobing it for b-actin and normalizing band intensity to the
b-actin signal.
Statistical analysis
Data were analyzed using GraphPad Prism 5.0 (GraphPad
Software Inc., La Jolla, CA). Experiments involving both wild type
and RAGE KO (2 variables; strain and treatment) were analyzed
by two-way analysis of variance with a Bonferonni post hoc test.
Data with one variable were analyzed by a Mann-Whitney test or
one-way analysis of variance followed by a Tukey’s post hoc test. All
values are expressed as means (6SEM). p,0.05 was considered
significant.
Results
Wild type and RAGE KO mice have similar degrees of
inflammation after LPS treatment
Twenty-four hours after i.t. challenge with LPS or vehicle
control, mice were sacrificed and assayed for various indicators of
acute pulmonary inflammation. Injury was assessed by measuring
total cell influx and differential cell counts in BALF, as well as
protein in BALF and myeloperoxidase activity of whole lung
homogenates. While the administration of LPS caused a significant
increase in cells and protein in the BALF (Figure 1A, D) compared
to the vehicle-treated mice (control), there was no difference
between wild type and RAGE KO mice. Differential cell counts
illustrate that the major cell type found in the BALF of controls
was the macrophage (Figure 1B). In contrast, after LPS challenge,
inflammatory cells in the BALF were almost exclusively neutro-
phils (Figure 1C). Myeloperoxidase activity, a measure of
neutrophil infiltration, after injury was also significantly increased
over the controls to a similar degree in lung homogenates from
both wild type and RAGE KO mice after LPS challenge
(Figure 1E).
RAGE KO mice have less inflammation than wild type
mice in response to E. coli challenge
Mice were sacrificed 24 hours after E. coli challenge. Both wild
type and RAGE KO mice exhibited significantly increased
cellularity (total cells/mL) in BALF after E. coli injury as compared
to control treated mice (Figure 2A). However, in contrast to LPS
injured mice, RAGE KO mice had a significantly lower E. coli-
induced increase in cellularity compared to wild type mice
(Figure 2A). Differential cell counts showed that after E. coli
challenge, RAGE KO mice had a significantly smaller decrease in
macrophages and a significantly reduced increase in neutrophils
compared to wild type mice (Figure 2B–C). Protein in the BALF
was used as a measure of lung permeability and hence injury. The
protein concentration in the BALF was significantly increased after
E. coli injury in both wild type and RAGE KOmice, with the latter
having a significantly lower increase than the wild type mice
(Figure 2D). Myeloperoxidase analysis also showed significantly
less activity in lung homogenates of RAGE KO compared to wild
type lungs (Figure 2E) after E. coli infection, consistent with the
lower levels of neutrophils observed in the RAGE-deficient mice.
Histology
Formalin fixed and paraffin embedded sections of lungs from all
groups were stained with H&E (Figure 3). Both wild type and
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Figure 1. Lack of RAGE does not protect against LPS-induced acute pulmonary inflammation. LPS challenge led to a significant increase
in total cells/mL in BALF for both wild type and RAGE KO mice (A). Differential cell counts showed that the increase in cells were mainly neutrophils
(B–C). However, there was no significant difference in response between wild type and RAGE KO mice. LPS challenge also led to a significant increase
RAGE in Acute Pulmonary Inflammation
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RAGE KO mice treated with vehicle control exhibited no
neutrophils and only occasional macrophages in the alveoli. After
LPS challenge, both wild type and RAGE KO mice had a
substantial, but similar influx of neutrophils into the alveolar space
consistent with the findings illustrated in Figure 1. While both wild
type and RAGE KO mice also had a substantial influx of
neutrophils into the alveolar lumen after injury with E. coli, the
RAGE KO mice appeared to have a lower degree of neutrophil
influx than wild type mice. This is consistent with the findings
illustrated in Figure 2.
RAGE expression decreases in the lungs after injury
Protein was extracted from control, LPS- and E. coli-challenged
wild type lungs. RAGE protein levels were assessed by western blot
analysis of soluble and membrane protein preparations from lung
tissue homogenates using a RAGE-specific primary antibody.
Significant decreases in all isoforms of RAGE protein were seen
after LPS and E. coli injury (Figure 4A–B). Interestingly, in
addition to the soluble and membrane RAGE bands (The two
lower bands in Figure 4A), an additional upper band of
approximately 53 kDa was also detected by western blotting. This
upper RAGE band has also been reported elsewhere [6,36]. This
additional RAGE isoform is likely an additional form of
membrane RAGE, since it is not present in soluble preparations
of whole-lung homogenate (Figure 4B).
Soluble RAGE and HMGB1 levels in BALF
The levels of soluble RAGE and HMGB1 in the BALF were
investigated by western blot analysis. Since no difference in
response to LPS between wild type and RAGE KO mice was
seen only the BALF from E. coli treated mice were assayed for
HMGB1. Soluble RAGE in the BALF increased significantly
after E. coli challenge compared to the controls in wild type mice
(Figure 5A). This finding is consistent with previous studies
[16,21]. Previous reports have found the level of HMGB1 to
approximately double in response to acute lung injury as
measured by ELISA [16]. By western blot analysis there is a
significant increase in the level of HMGB1 (Figure 5A–B) after E.
coli infection in both wild type and RAGE KO mice. A direct
comparison of HMGB1 levels in the BALF from E. coli treated
wild type and RAGE KO mice showed no significant difference
between the two (Figure 5C).
Cytokine profile of BALF
To identify potential differences in cytokines in the BALF of
wild type vs. RAGE KO mice after E. coli and LPS injury, BALF
samples were assayed for 7 known pro-inflammatory cytokines and
chemokines (Table 1). Both LPS and E. coli led to a significant
increase in all cytokines compared to the controls. After LPS
treatment, BALF levels of the chemokine MCP-1 was significantly
lower in the RAGE KO mice compared to wild type mice, while
all other cytokines were not significantly different between the two
strains. These data further support the notion that there are no
major differences in the response to LPS between wild type and
RAGE KO mice.
In contrast to the findings with LPS, RAGE KO mice had
significantly lower levels of all cytokines and chemokines except
the chemokine KC when compared to wild type mice in response
to E. coli infection. This finding is consistent with the other
measures of injury that indicate the RAGE KO mice have a lower
overall degree of inflammation after E. coli-induced pneumonia as
compared to wild type mice.
Lung slices
In order to further investigate the response towards LPS, wild-
type or RAGE KO lung slices were treated with vehicle or LPS
and then assayed for RNA expression of 5 known inflammatory
cytokines and chemokines (Table 2). In contrast to the cytokine
analysis of the BALF, there were significant differences in the
expression of all cytokines analyzed when this isolated lung system
was used. Lung slices from LPS-treated RAGE KO mice exhibited
a significantly higher expression of IL-1a, IL-1b and TNF-a and
significantly lower expression of IL-6 and MCP-1 compared to
LPS treated wild type lung slices.
Intraperitoneal administration of soluble RAGE does not
protect against E. coli induced acute pulmonary
inflammation
As loss of RAGE was found to protect against E. coli injury, wild
type mice were treated with soluble RAGE to determine if this
decoy receptor would offer protection. Mice received 100 mg of
purified mouse soluble RAGE by i.p. injection immediately before
E. coli challenge, and the effect of this treatment was assayed
24 hours later (Figure 6). This dose was based on a previous
publication in which the authors administered soluble RAGE to
LPS-challenged mice [16]; and this dose has also been found to be
effective in other non-pulmonary models of various diseases [37–
40]. Total cellularity in BALF after E. coli challenge with and
without mouse soluble RAGE treatment was not significantly
different. Mice that received E. coli in combination with mouse
soluble RAGE had slightly higher, but non-significant, cell counts,
which were mainly neutrophils (Figure 6A–C). Protein in BALF
and myeloperoxidase activity in lung homogenates were not
different when comparing E. coli-challenged mice receiving vehicle
control vs. mice receiving soluble RAGE i.p. (Figure 6D–E)
Intratracheal administration of soluble RAGE does not
protect against E. coli-induced acute pulmonary
inflammation
RAGE is a receptor for HMGB1 [25]. The hypothesized
therapeutic effect of soluble RAGE in LPS induced acute lung
injury is believed to occur via the ability of soluble RAGE to
function as a scavenger receptor for HMGB1 [16], thereby
decreasing pro-inflammatory, HMGB1-mediated responses. Be-
cause there was no effect of i.p. injection of soluble RAGE on E.
coli induced inflammation, an additional experiment was per-
formed in which mouse soluble RAGE was instilled i.t. to
determine if delivery of this protein directly to the site of injury
would ameliorate the inflammatory response. Mice received 50 mg
of purified mouse soluble RAGE. This dose was based on the
previous finding that one mouse lung contains approximately
75 mg of total soluble RAGE [31]. Hence, 50 mg of mouse soluble
RAGE is hypothesized to compensate for any soluble RAGE lost
as a result of injury. Figure 6 shows that i.t. instillation of soluble
RAGE had no effect on E. coli-mediated acute pulmonary
in protein in the BALF over the control treated animals to a similar degree for both wild type and RAGE KO mice (D). Myeloperoxidase activity in the
lung was also significantly increased in both strains after LPS injury, but no significant difference was seen between the two (E). Asterisks indicate
significant increase/decrease compared to vehicle control for each strain. Data are means (6SEM), analyzed by 2-way ANOVA with a Bonferroni post
hoc test (n of 4–11 per group).
doi:10.1371/journal.pone.0020132.g001
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Figure 2. RAGE KO mice get less inflammation than wild type mice after E. coli pneumonia. E. coli challenged RAGE KO mice had
significantly less total cells/mL in BALF compared to wild type mice (A). The lower amount of cells was mainly due to less neutrophils (B, C). Protein in
BALF (D) and myeloperoxidase activity of whole lung (E) were also significantly less in RAGE KO than in wild type mice after E. coli challenge.
* indicate significant increase/decrease compared to vehicle control for each strain. ** indicate significant difference between wild type and RAGE KO
mice. Data are mean 6SEM, analyzed by 2-way ANOVA with a Bonferroni post hoc test (n of 6–8 per group).
doi:10.1371/journal.pone.0020132.g002
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Figure 3. H&E stained lung sections from wild type and RAGE KO control, LPS and E. coli treated mice. The first column shows wild type
and the second column shows RAGE KO lungs. Macrophages (arrows) and neutrophils (arrowheads) in alveoli are indicated. First row is control
treated from both strains. A few macrophages are present in the alveoli of both control treated strains. LPS treatment, second row, led to a significant
infiltration of neutrophils into the alveolar space; however no immediate difference in degree of infiltration was noticeable between the strains. The
third row shows lung histology from E. coli treated mice. E. coli treated RAGE KO mice have fewer neutrophils compared to E. coli treated wild type
mice. Black bars represent 30 mm.
doi:10.1371/journal.pone.0020132.g003
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inflammation. There was no significant difference in cell
concentration in BALF between the mice receiving E. coli alone
and the mice that also received mouse soluble RAGE (Figure 6A).
Differential cell counts revealed an almost identical cell population
in mice receiving E. coli only and those receiving E. coli plus i.t.
mouse soluble RAGE (Figure 6B–C).
Protein levels in BALF were slightly lower in the group that
received both E. coli and i.t. soluble RAGE as compared to E. coli
alone, but this was not significant (Figure 6D). Myeloperoxidase in
total lung homogenate was not significantly different between the
two E. coli groups (Figure 6E). These results suggest that i.t.
instillation of soluble RAGE does not protect against the
inflammatory response to pulmonary E. coli infection.
Discussion
In the present study, the role of RAGE in pulmonary acute
inflammation was studied by comparing the responses of wild type
and RAGE KO mice to LPS and E. coli, and by treatment of E.
coli-infected wild type mice with purified soluble RAGE protein.
RAGE KO mice have been studied in bacterial pneumonia
previously [14] and soluble RAGE has been administered i.p. in
an LPS model of acute lung injury [16]. However, this is the first
study in which LPS-induced acute pulmonary inflammation has
been evaluated in RAGE KO mice. It is also the first time soluble
RAGE has been administered i.t and i.p to evaluate its therapeutic
potential in bacterial pneumonia.
RAGE expression is highest in the normal lung compared to all
other organs [5,7,10,41]. This seminal finding has given rise to
the hypothesis that RAGE must have an important function in
the normal lung [5]. Indeed, RAGE is expressed primarily on the
basolateral side of type I epithelial cells [9] and has been
suggested to be a marker of type I cell injury [18]. In addition,
RAGE KO mice have been shown to spontaneously develop
pulmonary fibrosis spontaneously with aging and increased
fibrosis in response to asbestos injury [5]. In contrast RAGE
KO mice are protected against bleomycin-induced pulmonary
fibrosis [11,42], and exhibit a similar degree of fibrosis as wild
type mice in a silica model of pulmonary fibrosis [8]. These
findings suggest that RAGE indeed has an important function in
the lung, but its effects differ depending on the inducing injury. In
the current study, RAGE protein expression was found to
significantly decrease in lung homogenates in response to two
models of acute pulmonary inflammation. This finding is
consistent with prior studies examining models of pulmonary
fibrosis in which RAGE levels decrease significantly after injury
in all models examined [5,7,8].
In contrast to the decrease of RAGE protein in the lung
homogenates there is an increase in soluble RAGE in the BALF in
wild type mice in response to E. coli injury. This is consistent with
previous studies that showed increased soluble RAGE in the BALF
after acute lung injury [16,21]. The source of the increase in
soluble RAGE in the BALF is unclear. However, the increased
soluble RAGE in the BALF may be the result of injury to type I
epithelial cells and subsequent release/cleavage of membrane
RAGE to soluble RAGE. It could also be secondary to soluble
RAGE being released from the extracellular matrix following
damage to the extracellular matrix structure, or by cleavage of
membrane RAGE from viable epithelial cells by proteases released
into the inflamed lung. Regardless of the mechanism, this finding
correlates well with the decrease in RAGE protein seen in the
western blots of the lung homogenates.
Figure 4. RAGE protein levels are decreased in the lungs after injury. Aliquots of 10 mg of protein from membrane or soluble protein
fractions from lung homogenates were assayed for RAGE expression by western blot analysis of RAGE and b-actin. Net intensity of RAGE expression
was normalized to b-actin. Membrane RAGE expression was significantly decreased after both LPS and E. coli challenge (A). Soluble RAGE expression
was significantly decreased after E. coli injury, and markedly, but not significantly decreased after LPS injury (p = 0.057 for LPS treatment). Normalized
net intensities were analyzed by a Mann-Whitney test. (* p,0.05, n of 4 mice per group).
doi:10.1371/journal.pone.0020132.g004
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Figure 5. HMGB1 levels are increased in the BALF of wild type and RAGE KO mice after E. coli injury. In addition, soluble RAGE is
increased in the BALF of wild type mice after E. coli injury. Aliquots of 35 mL BALF were loaded per lane. By western blot there is a significant increase
in the levels of soluble RAGE and HMGB1 in the BALF from wild type mice (A) and a significant increase of HMGB1 protein in the BALF of RAGE KO
mice (B) after E. coli injury. Direct comparison of HMGB1 levels between wild type and RAGE KO mice after E. coli injury (C) shows a similar level of
HMGB1 in BALF from both strains. Comparisons of protein levels were done by band densitometry analysis and analyzed by a Mann-Whitney test
(* p,0.05, n of 5 mice per group).
doi:10.1371/journal.pone.0020132.g005
Table 1. Cytokine profile of BALF from wild type and RAGE KO mice.
Control LPS E. coli
Wild type RAGE KO Wild type RAGE KO Wild type RAGE KO
IL-1b 3.960.5 3.460.2 24.261.7 28.562.1 16.761.1 9.560.6*
IL-6 2.960.01 2.960.02 201.2641.1 171.3623.1 134.1626.6 33.565.2*
IL-12(p70) 3.460.03 3.460.02 4.060.1 3.860.1 5.060.3 3.860.1*
KC ND ND 323.2649.6 421.3651.6 32.662.5 24.861.5
TNF-a ND ND 175.1616.8 159.8612.4 88.5612 36.663.2*
MIP-1a ND ND 78.163.5 87.166.2 27.062.1 16.261.4*
MCP-1 7.760.02 7.760.01 12046225 602.26124.8* 42613.4 14.761.8*
* = Significant difference between strains.
All cytokines were significantly up regulated after both LPS and E. coli treatment compared to the control treated. In addition MCP-1 was the only cytokine significantly
less increased in RAGE KO mice compared to wild type after LPS challenge. After E. coli treatment all cytokines except KC were increased significantly less in RAGE KO
mice compared to wild type mice. The most substantial differences were in IL-6, MCP-1 and TNF-a where levels were 4, 2.9 and 2.4 times higher in wild type BALF
compared to RAGE KO BALF.
*significant difference between wild type and RAGE KO (p,0.05).
Data are mean6SEM, analyzed by 2-way ANOVA with a Bonferroni post hoc test. (n of 5–7 per group). Abbreviations IL: interleukin, KC: keratinocyte-derived chemokine,
TNF: tumor necrosis factor, MIP: macrophage inflammatory protein, MCP: monocyte chemotactic protein.
doi:10.1371/journal.pone.0020132.t001
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RAGE KO mice have also been used to study the role of RAGE
in a Streptococcus pneumonia model, E. coli abdominal sepsis, and a
cecal ligation and puncture (CLP) model of polymicrobial sepsis
[14,15,43]. The Gram-positive bacterium Streptococcus pneumoniae
was used to induce pneumonia by i.t. instillation [14] and the
RAGE KO survival rate was found to be 19% after 8 days,
whereas all wild type mice had died by day 4. That study also
found the overall inflammatory response to be lower in the RAGE
KO mice, and that peritoneal macrophages from RAGE KO mice
exhibited increased bacterial killing in vitro. However, it was
unclear if the increase in bacterial killing by RAGE KO peritoneal
macrophages was due to actual increased killing potential or if
fewer bacteria were engulfed by the macrophages.
RAGE has also been shown to be an important mediator of
antibacterial activity. In a mouse model of E. coli-induced
abdominal sepsis, RAGE KO mice exhibited impaired antibac-
terial function compared to wild type mice [15]. In contrast, in a
CLP model of polymicrobial sepsis, RAGE KO mice demonstrat-
ed better survival than wild type mice. Furthermore, continuous
administration of soluble RAGE to wild type mice after CLP
improved survival by approximately 30% as compared to mice
treated with vehicle control [43]. These diverse studies point to the
importance of RAGE in inflammatory responses induced by
bacteria and LPS.
The current analysis of mice at a 24 hour time point did not
reveal any difference in inflammation between wild type and
RAGE KO mice treated with LPS, but did show that RAGE KO
mice were significantly protected compared to wild type mice
when challenged with live E. coli. To further investigate what
might explain this difference, the cytokine/chemokine profile was
analyzed in BALF from treated mice. Since the concentration of
MCP-1 in the BALF after LPS challenge was nearly 2-fold higher
in the wild type mice compared to RAGE KO mice, one would
expect more macrophages in the BALF of wild type mice.
However, Figure 1B illustrates that while macrophage levels are
slightly elevated in the wild type mice compared to RAGE KO
mice, there is no significant difference between the two.
After E. coli challenge, the cytokines IL-6 and TNF-a as well as
the chemokine MCP-1 were most substantially increased in wild
type as compared to RAGE KO mice. IL-6 is secreted by
macrophages, and is substantially increased in the BALF of
humans in the early phase ARDS. The expression of IL-6 is partly
regulated by TNF-a and IL-1b [44]. TNF-a is secreted from
stimulated monocytes and is up regulated by IL-1 and LPS [45].
MCP-1 recruits monocytes, but not neutrophils from the
bloodstream to sites of tissue injury and inflammation [46].
Furthermore, TNF-a signaling activates NF-kB, which drives the
expression of numerous pro-inflammatory cytokines and chemo-
kines, including MCP-1 [45]. While at this point the exact role of
RAGE in the inflammatory response to live E. coli is unknown, the
decreased levels of cytokines certainly point to an overall decrease
in the inflammatory response and cascade of pro-inflammatory
cytokine signaling in the RAGE KO mice.
These data are partly supported by the lung slice analysis, in
that MCP-1 was also significantly higher after LPS treatment in
wild type compared to RAGE KO lung slices. A much more
profound difference in the response to LPS was observed in
isolated lung slices as compared to the BALF from the live mouse.
This difference is mostly likely explained by the much more
sophisticated response towards LPS in the live organism compared
to an isolated system, and may imply that RAGE is involved in
LPS-induced expression of cytokines that remain tissue-associated,
vs. cytokines that are secreted into the BALF. Alternatively, RAGE
may modulate cytokine/chemokine mRNA expression in a
manner that does not translate to the protein level.
RAGE is a receptor for HMGB1, which is an important
mediator of the inflammatory response in acute lung injury
[47,48] and sepsis [43]. In the present study, HMGB1 levels in the
BALF from E. coli-infected wild type and RAGE KO mice were
not significantly different between the two strains. The lack of
RAGE in RAGE KO mice might be predicted to lower
inflammation, due to lack of RAGE-mediated inflammatory
response induced by HMGB1. However, this prediction is
complicated by the presence of soluble RAGE in wild type mice
that can scavenge HMGB1, thereby yielding the same overall
response as that seen in RAGE KO mice. The finding that soluble
RAGE treatment did not protect against E. coli infection suggests
that membrane RAGE signaling is of primary importance in this
model. Alternatively, this finding may suggest that soluble RAGE
treatment, regardless of delivery method, is not reaching the
correct compartment (i.e. basement membrane side of type 1
epithelial cells) to be effective.
A recent study found that i.p. administration of recombinant
mouse soluble RAGE one hour after i.t. LPS challenge
ameliorated the inflammatory response [16]. This finding led to
the hypothesis that soluble RAGE could potentially be used as a
therapy for patients hospitalized with acute lung injury or ARDS.
The therapeutic action of soluble RAGE was suggested to be due
to its ability to sequester HMGB1 and thereby function as a decoy
molecule, preventing HMGB1 signaling via other pattern
recognition receptors. To investigate this possibility in the current
study, wild type mice were treated with soluble RAGE purified
directly from mouse lungs. However, in contrast to the previous
study on the effects of soluble RAGE on LPS-induced inflamma-
tory responses [16], the current experiments suggest that
exogenously administered soluble RAGE did not have any
therapeutic, protective or ameliorative effect on E. coli pneumonia.
Additional studies are necessary in order to determine if the
difference in effects in these studies is due to the source of soluble
RAGE, the experimental paradigm used, or other factors. As
shown in a study investigating the effect of simultaneous
administration of LPS i.t. and i.p., removal of LPS from injectable
agents is very important [49]. A 30% decrease in neutrophil
infiltration of the lung was observed in rats that received i.p.
injections of LPS in addition to i.t. LPS compared to rats receiving
only i.t. LPS. This finding suggests that any observed effect of
Table 2. Cytokine RNA quantity in lung slices.
Control LPS
Wild type RAGE KO Wild type RAGE KO
IL-1a 0.0360.01 0.0160.00 0.1160.01 0.1960.02*
IL-6 0.3660.06 0.0860.02 1.0060.09* 0.460.03
IL-1b 0.0860.01 0.0760.02 0.2560.02 0.4960.04*
TNF-a 0.0160.00 0.0160.00 0.0260.1 0.160.01*
MCP-1 0.2060.03 0.0560.01 2.060.38* 0.6360.01
* = Significant difference between strains.
IL-1a, IL-1b, and TNF-a levels were all significantly higher in LPS treated RAGE
KO lung slices compared to wild type after LPS challenge. IL-6 and MCP-1 were
both higher in the LPS treated wild type lung slices compared to LPS treated
RAGE KO.
*significant difference between wild type and RAGE KO (p,0.05).
Data are mean 6SEM, analyzed by 2-way ANOVA with a Bonferroni post hoc
test. (n of 3 per group). Abbreviations IL: interleukin, TNF: tumor necrosis factor,
MCP: monocyte chemotactic protein.
doi:10.1371/journal.pone.0020132.t002
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Figure 6. Injection of mouse soluble RAGE (msRAGE) i.p. prior to E. coli challenge or i.t. co-treatment with E. coli and mouse soluble
RAGE did not affect the inflammatory response. Wild type mice only were used for these experiments. Total cells in the BALF and differential
cell counts showed no significant difference between E. coli mice given vehicle control or i.p. or i.t. msRAGE (A–C). Furthermore, protein in BALF
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injecting soluble RAGE, if not LPS-free, could be due to a
diversion of the inflammatory response to the site of soluble RAGE
administration. The soluble RAGE used in the current study
consistently tested well below the FDA guidelines of 5 EU/kg/
day. The lack of a direct increase in neutrophil levels in the BALF
after i.t. instillation of soluble RAGE only further confirms the
absence of LPS contamination. While a recent study found that
soluble RAGE can act as a chemotactic stimulus for neutrophils
both in vivo and in vitro (34), the present study illustrates that when
mouse soluble RAGE is administered by i.t. instillation without
other treatments, it does not appear to induce an increase of
neutrophils in the BALF. Instead, it led to a slight non-significant
increase in macrophages (not illustrated).
The data from the Streptococcus pneumoniae study [14], taken
together with the data from the current study, strongly suggests
that RAGE is involved in the pulmonary inflammatory response to
live bacteria. It is important to note that Streptococcus pneumoniae is a
Gram-positive bacterium, and therefore does not express LPS but
instead expresses lipoteichoic acid in its cell wall. E. coli, on the
other hand, is a Gram-negative bacterium and expresses LPS on
its cell wall. The inflammatory responses of the RAGE KO mice
were significantly lower when compared to that of wild type mice
in both of these models of live bacterial pneumonia. In contrast,
LPS-treated RAGE KO mice did not exhibit different inflamma-
tory responses when compared to wild type mice. Hence, the role
of RAGE in mediating pulmonary inflammation in response to
bacterial infection seems to be independent of LPS.
In summary, the studies described herein with wild type versus
RAGE KO mice suggest that RAGE does contribute to the
inflammatory response within the first 24 hours after E. coli
infection. Furthermore, the effect of treatment with various doses
and sites of delivery of mouse soluble RAGE showed no protective
effects against E. coli-induced inflammation. The true role of
RAGE will require additional studies, especially to determine if the
effects that have been reported using RAGE KO mice are due to
changes in the expression of other molecules that compensate for
the lack of RAGE in these constitutive knockout mice.
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